[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 13001
46. Huang J, Ni W, Wang L, Zhou W, Jin J: A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection. Int J Hematol; 2008 Jun;87(5):553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection.
  • [MeSH-major] Cytomegalovirus Infections / immunology. Killer Cells, Natural / immunology. Leukemia, Monocytic, Acute / immunology

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jun 15;97(12):3902-9 [11389033.001]
  • [Cites] Blood. 1999 Jan 1;93(1):96-106 [9864151.001]
  • [Cites] Bone Marrow Transplant. 1997 Mar;19(5):471-80 [9052914.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):621-5 [9207410.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 15;417(2):141-52 [12941295.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):117-9 [16631250.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Exp Hematol. 1997 Nov;25(12):1278-85 [9357972.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2186-94 [16179910.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1361-7 [16791270.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):578-84 [7646997.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4883-98 [9671497.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Eur J Haematol. 2006 Jan;76(1):86-8 [16343277.001]
  • (PMID = 18437504.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin; CROP protocol
  •  go-up   go-down


47. Chai YH, Lü H, Li JQ, Lu J, Xiao PF, He YX, Shao XJ: [Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 Sep;45(9):684-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia].
  • OBJECTIVE: In childhood acute lymphoblastic leukemia (ALL), cytogenetics plays an important role in diagnosis, allocation of treatment and prognosis.
  • Multiplex polymerase chain reaction (Multiplex PCR) analysis was performed to detect the 29 most common leukemia translocations for routine molecular diagnostic hematopathology practice, and complement the information gained from conventional cytogenetic analysis.
  • Thirteen cases of TEL-AML1, 10 cases of rearrangement in the MLL gene, 4 cases of E2A-PBX1, 4 cases of E2A-HLF, 3 cases of BCR-ABL, 2 cases of TLS-ERG, 32 cases of HOX11 were detected by Multiplex PCR in B-lineage leukemias.
  • SIL-TAL1 had been found in 4 of 7 of T-lineage leukemias.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit / genetics. Cytogenetic Analysis. Karyotyping. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Basic Helix-Loop-Helix Transcription Factors / genetics. Child. Child, Preschool. DNA-Binding Proteins / genetics. Female. Fusion Proteins, bcr-abl / genetics. Gene Fusion / genetics. Homeodomain Proteins. Humans. Immunophenotyping / methods. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Polymerase Chain Reaction. Proto-Oncogene Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021563.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / TEL-AML1 fusion protein; 0 / pbx1 protein, human; 135471-20-4 / TAL1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


48. Maule MM, Merletti F, Pastore G, Magnani C, Richiardi L: Effects of maternal age and cohort of birth on incidence time trends of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):347-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of maternal age and cohort of birth on incidence time trends of childhood acute lymphoblastic leukemia.
  • Several studies report increasing trends in the incidence of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301270.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT: Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Rev Anticancer Ther; 2007 May;7(5):741-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gene expression of acute myeloid leukemia in response to chemotherapy.
  • Such variation in gene expression may be the cause of different disease outcome and may reflect disease phenotypes or chemoresistance.
  • Acute myeloid leukemia is a malignant disease of the bone marrow where overall long-term disease-free survival is less than 50%.
  • The need for better disease classification and evaluation is consequently evident.
  • Gene expression profiling in acute myeloid leukemia has, in recent years, proven able to distinguish acute myeloid leukemia subclasses and predict clinical outcome and is, as such, a promising technique for improved disease evaluation.
  • The early detection of gene expression in response to chemotherapy may be a novel way of monitoring disease management.
  • The immediate gene response may be an indication of whether the drug of choice is efficient in leukemic cell eradication and may early indicate the need for other therapeutic measures.
  • Furthermore, these early alterations in gene expression could facilitate identification of new treatment targets, thereby enabling better patient care and follow-up in the future.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Monitoring / methods. Gene Expression / drug effects. Gene Expression Profiling. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Tumor Suppressor Protein p53 / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492937.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 80
  •  go-up   go-down


50. Inaba H, Jones DP, Gaber LW, Shenep JL, Call SK, Pui CH, Razzouk BI: BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia. J Pediatr; 2007 Aug;151(2):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.
  • We report a case of BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurovirol. 1996 Dec;2(6):411-6 [8972423.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):527-30 [12181409.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):1967-73 [10900035.001]
  • [Cites] Transplantation. 2006 Jan 15;81(1):117-20 [16421486.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):354-60 [16007533.001]
  • [Cites] Am J Transplant. 2005 Aug;5(8):1997-2004 [15996251.001]
  • [Cites] Pediatr Nephrol. 2005 Jun;20(6):782-5 [15782299.001]
  • [Cites] Leukemia. 1998 Apr;12(4):619-22 [9557622.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):528-37 [15712075.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1157-8 [15784677.001]
  • (PMID = 17643782.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-29; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-29
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Other-IDs] NLM/ NIHMS28072; NLM/ PMC2077844
  •  go-up   go-down


51. Ploner C, Rainer J, Lobenwein S, Geley S, Kofler R: Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Apoptosis; 2009 Jun;14(6):821-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
  • Glucocorticoid (GC)-induced apoptosis plays a major role in the treatment of acute lymphoblastic leukemia (ALL) and related malignancies.
  • Members of the BCL2 family of pro- and anti-apoptotic proteins are regulated by GC, but to what extent these regulations contribute to GC-induced cell death and resistance development is poorly understood.
  • Using primary lymphoblasts from ALL children during systemic GC monotherapy and related cell lines, we have previously shown that the response of the BCL2 rheostat to GC was dominated by induction of the pro-apoptotic BH3-only molecules BMF and BCL2L11/Bim, but we also observed an unexpected significant repression of the pro-apoptotic BCL2 protein PMAIP1/Noxa.
  • Prevention of GC-mediated Noxa repression by conditional expression of transgenic Noxa changed the kinetics of GC-induced apoptosis to resemble cell death induced by BimEL alone.
  • [MeSH-major] Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis Regulatory Proteins / metabolism. Bcl-2-Like Protein 11. Cell Line, Tumor. Gene Expression Regulation, Leukemic / drug effects. Humans. Kinetics. Membrane Proteins / metabolism. Myeloid Cell Leukemia Sequence 1 Protein. Proteasome Endopeptidase Complex / metabolism. Protein Processing, Post-Translational / drug effects. Proto-Oncogene Proteins / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421859.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18747
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BCL2L11 protein, human; 0 / Bcl-2-Like Protein 11; 0 / Bcl2l11 protein, rat; 0 / Glucocorticoids; 0 / Membrane Proteins; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / PMAIP1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


52. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr; 2006 Jun;95(6):701-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
  • AIM: To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute lymphoblastic leukaemia (ALL).
  • RESULTS: There was a correlation between level and avidity of tetanus antibodies after vaccination (r(s) = 0.59, P < 0.001).
  • [MeSH-major] Antibodies, Bacterial / immunology. Antibody Affinity. Haemophilus Vaccines / immunology. Haemophilus influenzae / immunology. Polysaccharides, Bacterial / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • Genetic Alliance. consumer health - Tetanus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754551.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Polysaccharides, Bacterial; 0 / Tetanus Toxoid
  •  go-up   go-down


53. Chang WR, Park IJ, Lee HW, Park JS, Kim HC, Kim HJ, Han JH, Cho SR: [Two cases of acute myeloid leukemia with t(16;21)(p11;q22) and TLS/FUS-ERG fusion transcripts]. Korean J Lab Med; 2009 Oct;29(5):390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of acute myeloid leukemia with t(16;21)(p11;q22) and TLS/FUS-ERG fusion transcripts].
  • One patient was a 24 yr-old male with acute myelomonocytic leukemia.
  • Although he received allogeneic peripheral blood stem cell transplantation after the first remission, he died 9 months after the initial diagnosis due to relapse of the disease and graft-versus-host disease.
  • The other patient was a 72 yr-old male with acute myeloid leukemia without maturation.
  • [MeSH-major] Chromosomes, Human, Pair 16 / genetics. Chromosomes, Human, Pair 22 / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Protein FUS / genetics. Translocation, Genetic
  • [MeSH-minor] Aged. Graft vs Host Disease / diagnosis. Humans. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893346.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Protein FUS; 0 / TLS-ERG fusion protein, human
  •  go-up   go-down


5
Advertisement
4. Prebet T, Lhoumeau AC, Arnoulet C, Aulas A, Marchetto S, Audebert S, Puppo F, Chabannon C, Sainty D, Santoni MJ, Sebbagh M, Summerour V, Huon Y, Shin WS, Lee ST, Esterni B, Vey N, Borg JP: The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood; 2010 Sep 30;116(13):2315-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome.
  • The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway.
  • We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation.
  • Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model.
  • In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis.
  • Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein.
  • We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. Receptor Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Anthracyclines / pharmacology. Antibiotics, Antineoplastic / pharmacology. Apoptosis. Base Sequence. Cell Line, Tumor. Cell Movement. Cell Polarity. Cytogenetic Analysis. DNA Primers / genetics. Drug Resistance, Neoplasm. HL-60 Cells. Humans. Immunophenotyping. In Vitro Techniques. Jurkat Cells. K562 Cells. Prognosis. Treatment Outcome. U937 Cells

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20558616.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cell Adhesion Molecules; 0 / DNA Primers; EC 2.7.1.- / PTK7 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


55. Kamble RT, Hjortsvang E, Selby GB: Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Jun;12(6):691-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Humans. Leukemia, Myeloid. Transplantation, Homologous. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7 [16399569.001]
  • (PMID = 16737944.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


56. Meshinchi S, Appelbaum FR: Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res; 2009 Jul 1;15(13):4263-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and functional alterations of FLT3 in acute myeloid leukemia.
  • Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell populations.
  • Exploring the mechanisms by which these FLT3 alterations lead to dysregulated proliferation should provide a better understanding of the molecular pathogenesis of acute myeloid leukemia (AML) and may provide insights into potential therapeutic interventions.


57. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood; 2008 Feb 15;111(4):1827-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
  • An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Humans. Middle Aged. Recurrence. Risk Factors. Siblings. Survival Analysis. Transplantation, Autologous. Transplantation, Homologous


58. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • All patients received cyclosporine-A (CsA) and methotrexate as graft vs. host disease (GvHD) prophylaxis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


59. Bain BJ: Hemophagocytosis evolving into acute lymphoblastic leukemia. Am J Hematol; 2005 Mar;78(3):246-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemophagocytosis evolving into acute lymphoblastic leukemia.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Hematol. 2004 Aug;76(4):364-7 [15282670.001]
  • (PMID = 15726603.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


60. Karrman K, Andersson A, Björgvinsdóttir H, Strömbeck B, Lassen C, Olofsson T, Nguyen-Khac F, Berger R, Bernard O, Fioretos T, Johansson B: Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. Eur J Haematol; 2006 Jul;77(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
  • OBJECTIVES: The t(12;14)(p13;q11)--a recurrent translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL)--has very recently been molecularly characterized in one case, which displayed overexpression of the cyclin D2 gene (CCND2).
  • RESULTS: FISH revealed breakpoints (BPs) in the T-cell receptor alpha/delta locus (14q11) and in the vicinity of the CCND2 gene at 12p13.
  • Neither PARP11 nor FGF23 displayed expression differences among the T-ALLs, whereas CCND2 was clearly overexpressed in both t(12;14)-positive cases as compared to the mean expression level in the controls.
  • Furthermore, it is the first example of a T-cell neoplasm with a targeted deregulation of a member of a cyclin-encoding gene family.
  • [MeSH-major] Cyclins / genetics. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548914.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


61. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J, Cooperative German Transplant Study Group: Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood; 2005 Nov 1;106(9):3314-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
  • Seventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase 2 study on reduced-intensity myeloablative conditioning with fractionated 8-Gy total body irradiation (TBI) and fludarabine (120 mg/m2).
  • Thirty-six patients received a transplant in complete remission (CR) and 35 had untreated or refractory disease (non-CR).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives. Whole-Body Irradiation
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


62. Wang L, Zhang LP, Li ZG, Cheng YF, Tian KG, Lu AD: [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2005 Mar;43(3):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
  • OBJECTIVE: Hematologic relapse remains the greatest obstacle to the cure of acute lymphoblastic leukemia (ALL), especially T-lineage acute lymphoblastic leukemia (T-ALL) in children.
  • Recent studies have shown that patients with increased risk of relapse can be identified by measuring residual leukemic cells, called minimal residual disease (MRD), during clinical remission.
  • (2) The RQ-PCR assay had a sensitivity of detection of one leukemic cell among 100,000 normal cells.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Gene Deletion. Polymerase Chain Reaction / methods. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833185.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


63. Zada AA, Geletu MH, Pulikkan JA, Müller-Tidow C, Reddy VA, Christopeit M, Hiddemann WD, Behre HM, Tenen DG, Behre G: Proteomic analysis of acute promyelocytic leukemia: PML-RARalpha leads to decreased phosphorylation of OP18 at serine 63. Proteomics; 2006 Nov;6(21):5705-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of acute promyelocytic leukemia: PML-RARalpha leads to decreased phosphorylation of OP18 at serine 63.
  • In the present study, we employed 2-DE to characterize the effect of the acute promyelocytic leukemia (APL)-specific PML-RARalpha fusion protein on the proteome.
  • Differentially expressed proteins, a number of which are related to the cell cycle function, including oncoprotein18 (OP18), heat shock protein70, glucose-regulated protein75, and peptidyl-prolyl isomerase, were identified by MS.
  • PML-RARalpha induction also leads to decreased phosphorylation on Ser63 residue of OP18, which is okadaic acid sensitive suggesting the involvement of a phosphatase pathway.
  • Overexpression of a constitutively phosphorylated Ser63 mutant of OP18 in PML-RARalpha expressing APL patient, PR9, and NB4 cells led to a G2/M-phase arrest in contrast to a phosphorylation-deficient Ser63 mutant and untransfected control.
  • Taken together, our results demonstrate the significance of decreased Ser63 phosphorylation of OP18 in PML-RARalpha-mediated effects on cell cycle.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / metabolism. Oncogene Proteins, Fusion / analysis. Proteome / analysis. Serine / metabolism. Stathmin / metabolism
  • [MeSH-minor] Cell Line. Clone Cells. Computational Biology / methods. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Genes, Reporter. Humans. Luciferases / metabolism. Mass Spectrometry. Mutation. Peptide Mapping. Phosphorylation. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Structure, Secondary. Proteomics / methods. RNA, Messenger / metabolism. Recombinant Fusion Proteins / metabolism. Transfection. U937 Cells. Zinc Sulfate


64. Chan MS, Roebuck DJ, Yuen MP, Li CK, Chan YL: MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging. AJNR Am J Neuroradiol; 2006 Mar;27(3):548-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.
  • BACKGROUND AND PURPOSE: Hemosiderin and white matter lesions are 2 of the most common neurologic complications found on MR imaging that may be related to cranial irradiation and intrathecal methotrexate (MTX) therapy in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Brain / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551991.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


65. Seror E, DeVillartay P, Leverger G, Lenoir G: [HHV-6 infection and acute lymphoblastic leukemia in a child]. Arch Pediatr; 2008 Jan;15(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HHV-6 infection and acute lymphoblastic leukemia in a child].
  • We report the case of a child who was infected by HHV-6 and who started an acute lymphoblastic leukemia two months later.
  • This case reminds that an etiologic role have been suggested for many viral infections in some leukemias in childhood, particularly the human herpesvirus 6 (HHV-6).
  • [MeSH-major] Herpesvirus 6, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Roseolovirus Infections / complications
  • [MeSH-minor] Blast Crisis. Blood Cell Count. Child, Preschool. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162384.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Cory JG, Cory AH: Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo; 2006 Sep-Oct;20(5):587-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
  • Asparaginase is a key component of the chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL).
  • Glutamine is a required substrate for three enzymes involved in the de novo synthesis of purine nucleotides and two enzymes involved in the de novo synthesis of pyrimidine nucleotides.
  • In this review, the specific roles of glutamine in the de novo synthesis of nucleotides are defined and an appropriate explanation for the cell cycle arrest and cytotoxicity induced in proliferating malignant lymphoblasts by asparaginase treatment is provided.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Glutamine / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Purine Nucleotides / biosynthesis. Pyrimidine Nucleotides / biosynthesis
  • [MeSH-minor] Cell Cycle. Molecular Structure. Nitrogen / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091764.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Purine Nucleotides; 0 / Pyrimidine Nucleotides; 0RH81L854J / Glutamine; EC 3.5.1.1 / Asparaginase; N762921K75 / Nitrogen
  • [Number-of-references] 7
  •  go-up   go-down


67. Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX: [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):435-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the clinical characteristics of adult acute lymphoblastic leukemia (ALL), compare the efficacy of different induction regimens and analyze the prognostic factors.
  • With a median follow-up of 14.5 (1-75) months, the median disease free survival (DFS) was 12 (1-74) months and median overall survival (OS) 17.5 (1-97) months.
  • 3) COX regression analysis showed that the age (over 40 years), white blood cell (WBC) count ( > 40 x 10(9)/L) , t(9;22) (q34;q11)-positive and less than 4 courses consolidation chemotherapy were the unfavorable prognostic factors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035173.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


68. Harrison CJ, Griffiths M, Moorman F, Schnittger S, Cayuela JM, Shurtleff S, Gottardi E, Mitterbauer G, Colomer D, Delabesse E, Castéras V, Maroc N: A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet; 2007 Feb;173(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
  • Rearrangements of the MLL gene are significant in acute leukemia.
  • Among the most frequent translocations are t(4;11)(q21;q23) and t(9;11)(p22;q23), which give rise to the MLL-AFF1 and MLL-MLLT3 fusion genes (alias MLL-AF4 and MLL-AF9) in acute lymphoblastic and acute myeloid leukemia, respectively.
  • Current evidence suggests that determining the MLL status of acute leukemia, including precise identification of the partner gene, is important in defining appropriate treatment.
  • A novel molecular diagnostic device, the MLL FusionChip, has been successfully used to identify MLL fusion gene translocations in acute leukemia, including the precise breakpoint location.
  • The type of molecular information provided by MLL FusionChip gave an indication of the appropriate primers to design for disease monitoring of MLL patients following treatment.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Chromosomes, Human, Pair 9. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Oligonucleotide Array Sequence Analysis / instrumentation. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2007 Dec;179(2):167
  • (PMID = 17284365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


69. Vaudre G, Parker JL, Leverger G: [Living after an acute lymphoblastic leukemia]. Soins Pediatr Pueric; 2006 Jun;(230):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Living after an acute lymphoblastic leukemia].
  • [MeSH-major] Adaptation, Psychological. Adolescent, Hospitalized / psychology. Attitude to Health. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Psychology, Adolescent


70. Onda K, Iijima K, Katagiri YU, Okita H, Saito M, Shimizu T, Kiyokawa N: Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma. Int J Hematol; 2010 Jun;91(5):808-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.
  • B cell-activating factor belonging to the tumor necrosis factor superfamily (BAFF) is a crucial factor for B cell development and is involved in the survival of malignant B cells, but its effect on B cell precursors (BCPs) remains unclear.
  • We investigated BCP acute lymphoblastic leukemia (-ALL) cells for BAFF receptor (-R) expression and compared the effect of BAFF on BCP-ALL cells and Burkitt lymphoma (BL) cells.
  • Expression of BAFF-R was detected in some cell lines and some clinical specimens of both BL and BCP-ALL.
  • BAFF also inhibited apoptosis by BL cells induced by cross-linking of cell surface molecules and anticancer drugs, but failed to inhibit apoptosis by BCP-ALL cells.
  • The results of this study indicate that some BCP-ALL cells and some BL cells express BAFF-R, but that the effects of BAFF on BCP-ALL cells are different from its effects on mature B cell malignancies.
  • [MeSH-major] B-Cell Activating Factor / immunology. B-Cell Activation Factor Receptor / genetics. Burkitt Lymphoma / immunology. Gene Expression Regulation, Leukemic. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / pathology
  • [MeSH-minor] Antigens, CD40 / immunology. Apoptosis. Cell Line, Tumor. Cell Proliferation. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2003 Jul 15;171(2):547-51 [12847217.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):137-43 [10880535.001]
  • [Cites] Immunology. 2006 Jul;118(3):281-92 [16827889.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):680-3 [10331498.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15978-81 [10347144.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):177-84 [18510703.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):995-9 [10801128.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35478-85 [10956646.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5567-77 [11313396.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):327-36 [17433868.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18656-65 [9228035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9156-61 [10908663.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5820-3 [12794106.001]
  • [Cites] Immunity. 2002 Oct;17(4):515-24 [12387744.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):252-60 [12496407.001]
  • [Cites] Histopathology. 2009 Jan;54(2):221-32 [19207947.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):785-8 [10898980.001]
  • [Cites] Immunology. 2008 Dec;125(4):570-90 [18540961.001]
  • [Cites] Blood. 2007 Jan 15;109(2):729-39 [16960154.001]
  • [Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]
  • [Cites] Exp Hematol. 2006 Apr;34(4):508-18 [16569597.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5 [10716715.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):282-9 [15886118.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2111-4 [11509691.001]
  • [Cites] Clin Exp Immunol. 1990 Mar;79(3):322-7 [2138527.001]
  • [Cites] Exp Hematol. 2002 Oct;30(10):1115-23 [12384141.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):129-35 [10880534.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1164-74 [12764385.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Int Immunol. 1995 Jul;7(7):1093-106 [8527407.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3015-23 [15728515.001]
  • [Cites] Immunity. 2001 Aug;15(2):289-302 [11520463.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3096-104 [7534787.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1113-9 [16226112.001]
  • (PMID = 20428981.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / B-Cell Activating Factor; 0 / B-Cell Activation Factor Receptor
  •  go-up   go-down


71. Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I: Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett; 2010 Oct 30;133(2):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct inhibition of human acute myeloid leukemia cell growth by IL-12.
  • Acute myeloid leukemia is a haematopoietic malignancy originating from the transformation of myeloid progenitors that proliferate and accumulate in the bone marrow.
  • In this study we have asked whether IL-12, an immuno-modulatory cytokine with anti-tumor activity, may inhibit directly AML cell growth.
  • We show that the human AML cell lines U937, K562 and THP-1 expressed both chains of the IL-12 receptor (R), i.e.
  • In vivo experiments were performed using SCID-NOD mice injected intraperitoneally (i.p.) with the human U937 AML cell line and subsequently treated with human recombinant IL-12 or PBS i.p.
  • Histological, immunohistochemical and flow cytometric analyses on explanted tumors revealed that IL-12 reduced new vessel formation, induced apoptosis and inhibited tumor cell proliferation.
  • This study shows for the first time that IL-12 targets directly AML cell growth and paves the way to further investigation of IL-12 as potential drug for AML treatment.
  • [MeSH-major] Cell Proliferation / drug effects. Growth Inhibitors / administration & dosage. Interleukin-12 / administration & dosage. Leukemia, Myeloid, Acute / immunology. Receptors, Interleukin-12 / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20705102.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Growth Inhibitors; 0 / Receptors, Interleukin-12; 187348-17-0 / Interleukin-12
  •  go-up   go-down


72. Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, Li C, Erba H, Malek SN: NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res; 2010 Aug 15;16(16):4135-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF1 inactivation in adult acute myelogenous leukemia.
  • PURPOSE: This study was conducted to identify novel genes with importance to the biology of adult acute myelogenous leukemia (AML).
  • These NF1 mutations were already present in the hematopoetic stem cell compartment.
  • Subsequent expression analysis of NF1 mRNA in the entire AML cohort using fluorescence-activated cell sorting sorted blasts as a source of RNA identified six patients (one with a NF1 mutation) with absent NF1 expression.
  • CONCLUSIONS: NF1 null states are present in 7 of 95 (7%) of adult AML and delineate a disease subset that could be preferentially targeted by Ras or mammalian target of rapamycin-directed therapeutics.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1012-21 [18281475.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Blood. 2008 Aug 1;112(3):814-21 [18490517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1993-2003 [18436738.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4603-9 [18559876.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10349-57 [19074904.001]
  • [Cites] Cancer Cell. 2009 Jul 7;16(1):44-54 [19573811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5 [19651600.001]
  • [Cites] Clin Cancer Res. 2009 Nov 1;15(21):6732-9 [19843663.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):181-8 [10620616.001]
  • [Cites] Leukemia. 2000 Mar;14(3):513-7 [10720153.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):709-15 [11544276.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Aug 1;102(3):972-80 [12702506.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Blood. 1991 Mar 1;77(5):925-9 [1704804.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):534-40 [8249893.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50874-85 [15371411.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2527-34 [15550488.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3217-24 [15867216.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Biogerontology. 2005;6(3):185-92 [16041622.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):337-48 [16226708.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39524-33 [16169856.001]
  • [Cites] Leukemia. 2006 Apr;20(4):635-44 [16467864.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3887-94 [16864856.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Cancer Cell. 2006 Sep;10(3):179-90 [16959610.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1224-31 [17377590.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4777-85 [17699855.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1534-42 [17954704.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • [Cites] Leukemia. 2008 Feb;22(2):240-8 [18200041.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4322-8 [18172006.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):137-43 [8563750.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [CommentOn] Clin Cancer Res. 2010 Aug 15;16(16):4074-6 [20587590.001]
  • (PMID = 20505189.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136537; United States / NCI NIH HHS / CA / 1R01 CA136537-01; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA136537-02; United States / NCI NIH HHS / CA / CA136537-02
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS210184; NLM/ PMC2921448
  •  go-up   go-down


73. Charoensuk V, Gati WP, Weinfeld M, Le XC: Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol; 2009 Aug 15;239(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells.
  • Arsenic trioxide, As(2)O(3), has successfully been used to treat acute promyelocytic leukemia (APL).
  • To further understand the cytotoxicity of arsenic compounds in APL cells, HL-60 cells were exposed to graded concentrations of the following arsenicals for up to 48 h: arsenic trioxide (As(III)), sodium arsenate (As(V)), phenylarsine oxide (PAO(III)), monomethylarsonous acid (MMA(III)), monomethylarsonic acid (MMA(V)) and dimethylarsinic acid (DMA(V)), and the viability and modes of cell death assessed.
  • The arsenic-exposed cells were stained with annexin V-PE and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry in order to detect apoptotic and viable cells while cell morphology was visualized using scanning and transmission electron microscopy.
  • Acridine orange staining and microtubule-associated protein 1 light chain 3 (MAP-LC3) detection were used to recognize autophagic cell death.
  • [MeSH-minor] Caspase 3 / metabolism. Cell Survival / drug effects. Flow Cytometry. HL-60 Cells. Humans. Leukemia, Promyelocytic, Acute. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Microtubule-Associated Proteins / metabolism. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465042.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Microtubule-Associated Proteins; 0 / light chain 3, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


74. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R: Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia; 2008 Sep;22(9):1798-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Folic Acid / genetics. Methotrexate / adverse effects. Polymorphism, Genetic / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


75. Zeng DF, Kong PY, Chen XH, Wei L, Chang C, Peng XG: [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma]. Zhonghua Nei Ke Za Zhi; 2005 Jul;44(7):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].
  • OBJECTIVE: To analyze the expression of stromal cell derived factor-1 (SDF-1) and its functional chemokine receptor CXCR4 in patients with acute leukemia and malignant lymphoma.
  • The serum level of SDF-1 was determined with ELISA assay.
  • RESULTS: The expression of SDF-1 and CXCR4 in acute leukemia for ALL group, the expression of SDF-1 and CXCR4 is (7115.8 +/- 946.5) ng/L and (77.2 +/- 9.7)%; for ANLL group, the expression is (4642.2 +/- 1146.8) ng/L, (38.9 +/- 11.0)% and malignant lymphoma for HD group, the expression of SDF-1 and CXCR4 is (3728.9 +/- 690.9) ng/L and (9.2 +/- 2.7)%; for NHL group, the expression is (4442.1 +/- 1073.0) ng/L and (8.5 +/- 2.4)% patients were higher than that in controls the expression of SDF-1 and CXCR4 is (2369.3 +/- 966.5) ng/L and (2.7 +/- 1.5)% (P < 0.01).
  • In the leukemia group, the patients with extra-marrow infiltration have higher expression of SDF-1/CXCR4 than those without and the patients; in the lymphoma group.
  • CONCLUSIONS: The high expression of SDF-1 and CXCR4 is somewhat correlated with the pathogenetic process and infiltration characteristics of acute leukemia and malignant lymphoma.
  • [MeSH-major] Chemokines, CXC / blood. Leukemia, Myeloid, Acute / metabolism. Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, CXCR4 / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080846.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4
  •  go-up   go-down


76. Seror E, Coquerel B, Gautheret-Dejean A, Ballerini P, Landman-Parker J, Leverger G, Schneider P, Vannier JP: Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia. J Med Virol; 2008 Apr;80(4):689-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia is the main type of leukemia in children.
  • The potential role of HHV-6 in the pathogenesis of pediatric acute lymphoblastic leukemia was investigated.
  • HHV-6 genome copy number was measured by quantitative real-time PCR (RQ-PCR) in bone marrow or peripheral blood samples obtained from 36 children (median age = 4 years) with B acute lymphoblastic leukemia (n = 31) and T acute lymphoblastic leukemia (n = 5) at diagnosis and during complete remission.
  • A total of 24.7% of samples were positive for HHV-6 genome: 13.9% were leukemia samples and 34.1% were complete remission samples.
  • These results argue against a role of HHV6 infection in the development of pediatric acute lymphoblastic leukemia.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 6, Human / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / virology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / virology. Roseolovirus Infections / complications. Roseolovirus Infections / virology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297709.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


77. Vijayakrishnan J, Sherborne AL, Sawangpanich R, Hongeng S, Houlston RS, Pakakasama S: Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence. Leuk Lymphoma; 2010 Oct;51(10):1870-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence.
  • Recent genome-wide association (GWA) studies of childhood acute lymphoblastic leukemia (ALL) have identified 7p12.2, 9p21.3, 10q21.2, and 14q11.2 SNPs that confer modest risks of ALL.
  • Consistent with findings in European populations, rs4132601 genotype was significantly associated with risk of ALL (odds ratio [OR] = 1.57, 95% confidence interval [CI]: 1.01-2.44; p = 0.04), and rs10821938 genotype was significantly associated with B-cell precursor ALL (OR = 0.73, 95% CI: 0.55-0.97; p = 0.03).
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group / genetics. Case-Control Studies. Child. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genetic Predisposition to Disease / genetics. Genotype. Humans. Incidence. Linkage Disequilibrium. Male. Risk Factors. Thailand / epidemiology. Young Adult


78. Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA: Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol; 2008 Jun;62(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768625.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI068282-01; United States / NIAID NIH HHS / AI / R43 AI068282; United States / NIAID NIH HHS / AI / R43 AI068282-01
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol; 2010 Nov 1;28(31):4755-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
  • PURPOSE: In a previous analysis of 326 children with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL) treated between 1986 and 1996, hematopoietic stem-cell transplantation from HLA-matched related donors, but not from unrelated donors, offered a superior outcome than chemotherapy alone.
  • Transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5168-74 [19805690.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):345-54 [20010622.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):298-308 [20016530.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):320-34 [20016537.001]
  • [Cites] Leukemia. 2010 Feb;24(2):397-405 [20016538.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] Leukemia. 2010 Feb;24(2):383-96 [20033052.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Blood. 2010 Apr 22;115(16):3206-14 [20154213.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2004 Apr;18(4):693-702 [15044926.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Blood. 1991 Jan 15;77(2):324-30 [1985699.001]
  • [Cites] Lancet. 1991 May 4;337(8749):1055-8 [1673492.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2411-8 [1932753.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • (PMID = 20876426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA086011; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U24 CA114766
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Protein Kinase Inhibitors
  • [Other-IDs] NLM/ PMC3020705
  •  go-up   go-down


80. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T: ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.
  • BACKGROUND: A major issue in the treatment of acute myeloid leukemia (AML) is resistance to chemotherapeutic drugs.
  • Incubation of cell lines with a number of different cytostatic drugs induced an up-regulation of ABCA3.
  • [MeSH-major] ATP-Binding Cassette Transporters / physiology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics


81. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S, Japan Cord Blood Bank Network: Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood; 2009 Feb 19;113(8):1631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
  • We made a disease-specific comparison of unrelated cord blood (CB) recipients and human leukocyte antigen allele-matched unrelated bone marrow (BM) recipients among 484 patients with acute myeloid leukemia (AML; 173 CB and 311 BM) and 336 patients with acute lymphoblastic leukemia (ALL; 114 CB and 222 BM) who received myeloablative transplantations.
  • In multivariate analyses, among AML cases, lower overall survival (hazard ratio [HR]=1.5; 95% confidence interval [CI], 1.0-2.0, P= .028) and leukemia-free survival (HR=1.5; 95% CI, 1.1-2.0, P= .012) were observed in CB recipients.
  • In ALL, there was no significant difference between the groups for relapse (HR=1.4, 95% CI, 0.8-2.4, P= .19) and treatment-related mortality (HR=1.0; 95% CI, 0.6-1.7, P= .98), which contributed to similar overall survival (HR=1.1; 95% CI, 0.7-1.6, P= .78) and leukemia-free survival (HR=1.2; 95% CI, 0.9-1.8, P= .28).
  • Matched or mismatched single-unit CB is a favorable alternative stem cell source for patients without a human leukocyte antigen-matched related or unrelated donor.
  • [MeSH-major] Bone Marrow Transplantation / mortality. Cord Blood Stem Cell Transplantation / mortality. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Platelets / cytology. Cause of Death. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / epidemiology. Histocompatibility Testing. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neutrophils / cytology. Recurrence. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104080.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Yoshida M; Sato K; Kohda K; Kobayashi N; Kobayashi R; Fukuhara T; Masauji N; Suzuki N; Ishida T; Matsunaga T; Imamura M; Kaneda M; Nishio M; Sasaki S; Ogura K; Ishida Y; Endo M; Okuda M; Kameoka J; Sasahara Y; Mitsui T; Tajima K; Fujishima N; Ogawa K; Kikuta A; Takayama N; Okamoto S; Shimada H; Waki A; Mori S; Hagiwara S; Kumagai M; Hamano Y; Yanagisawa K; Tashiro H; Fukuda T; Kajiwara M; Kimura Y; Yano S; Yoshinaga K; Takahashi S; Takita J; Akiyama H; Kaneko T; Ueno H; Tajika K; Suzuki K; Hatta Y; Chin M; Sakai R; Fujita H; Goto H; Kanamori H; Kigasawa H; Inoue Y; Onizuka M; Yabe H; Takeuchi M; Tanaka H; Okimoto Y; Yokota A; Nakaseko C; Ishiwada N; Katayama T; Kawai N; Watabe R; Maseki N; Kikuchi A; Ohshima K; Kimura F; Kogawa K; Koike K; Kamoshita M; Hasegawa Y; Muroi K; Sasaki K; Sugita K; Sakura T; Saito T; Kanazawa T; Sugita K; Asami K; cho T; Furukawa T; Koike T; Ito T; Yanagisawa R; Ishii E; Kobayashi H; Naito K; Yagyu T; Takashima Y; Ikeda T; Yago K; Taguchi J; Shigeno K; Okada S; Mihara H; Morishima Y; Morishita Y; Sawa M; Hamaguchi M; Kusumoto S; Murata M; Kojima S; Kato K; Miyamura K; Kasai M; Shimokawa T; Sao H; Kawakami K; Nakase K; Azuma E; Tamaki S; Oka K; Yoshida T; Kanegane H; Fukushima T; Nishimura R; Takami A; Ymaguchi M; Tanizawa A; Kasahara S; Kito K; Doi S; Ito M; Kuroda H; Ichinohe T; Adachi S; Nakagawa H; Taniwaki M; Hatanaka K; Kishimoto Y; Ashida T; Sakata N; Ishida H; Yonetani N; Hara J; Yamane T; Tsudo M; Maeda T; Ohta H; Hiraoka A; Inoue M; Akasaka H; Usami I; Nagai K; Okamura A; Hayakawa A; Otsuka Y; Okada M; Murayama T; Kosaka Y; Yagi H; Nakamura F; Amano I; Higuchi B; Sonoki T; Endo A; Ago H; Okazaki T; Ueyama J; Maeda Y; Sayama K; Ueda Y; Sunami K; Hamamoto K; Iwato K; Kobayashi M; Niimi H; Yujiri T; Ohnishi H; Abe M; Togitani K; Hara M; Tauchi H; Narumi H; Muta T; Yakushiji K; Matsuzaki A; Nagafuji K; Abe Y; Kamimura T; Eto T; Morimoto H; Miyaji R; Imada K; Imamura Y; Uike N; Nagatoshi Y; Moriuchi Y; Miyazaki Y; Otsuka E; Ogata M; Morinaga S; Hidaka M; Otsuka M; Takatsuka Y; Matsushita K; Okamoto Y; Okamura T; Tomoyose T; Kaneda M; Nishio M; Imamura M; Tanaka J; Kobayashi R; Kobayashi N; Suzuki N; Ishida T; Matsunaga T; Yoshida M; Sato K; Kohda K; Masauji N; Fukuhara T; Sasaki S; Ogura K; Endo M; Ishida Y; Sasahara Y; Kameoka J; Okuda M; Meguro K; Imaizumi M; Watanabe A; Fujishima N; Mitsui T; Tajima K; Kikuta A; Ogawa K; Kimura H; Koike K; Komatsu T; Hasegawa Y; Kamoshita M; Muroi K; Sugita K; Sasaki K; Kanazawa T; Saito T; Sakura T; Kikuchi A; Kimura F; Shibuya A; Kawai N; Maseki N; Hirabayashi K; Watabe R; Ohshima K; Nakaseko C; Ishiwada N; Okimoto Y; Aotsuka N; Tanaka H; Yokota A; Takeuchi M; Katayama T; Ishii A; Takita J; Okamoto S; Shimada H; Mori S; Chin M; Hatta Y; Yano S; Kajiwara M; Fukuda T; Takahashi S; Kaku H; Akiyama H; Kumagai M; Yoshinaga K; Ueno H; Ohara A; Tajika K; Tashiro H; Waki A; Hagiwara S; Kozai Y; Suzuki K; Kikuchi T; Yanagisawa K; Kaneko T; Kimura Y; Hamano Y; Manabe A; Usuki K; Takayama N; Miyakoshi S; Yabe H; Onizuka M; Goto H; Fujita H; Sakai R; Kigasawa H; Kanamori H; Isoyama K; Sano F; Inoue Y; Sugita K; Iino M; Yanagisawa R; Ito T; Ishii E; Kobayashi H; Asami K; cho T; Koike T; Furukawa T; Yoshida T; Kanegane H; Nishimura R; Takami A; Fukushima T; Ymaguchi M; Tanizawa A; Kasahara S; Takao A; Yago K; Takashima Y; Shigeno K; Okada S; Naito K; Taguchi J; Yagyu T; Ikeda T; Kato K; Miyamura K; Kasai M; Hamaguchi M; Murata M; Kojima S; Morishita Y; Sao H; Emi N; Morishima Y; Kusumoto S; Sawa M; Mihara H; Oka K; Tamaki S; Azuma E; Nakase K; Kawakami K; Taga T; Kito K; Kuroda H; Ito M; Nakagawa H; Adachi S; Ichinohe T; Taniwaki M; Doi S; Hiraoka A; Ohta H; Maeda T; Inoue M; Kishimoto Y; Hara J; Teshima H; Ashida T; Sakata N; Ishida H; Uoshima N; Kazumi Y; Yamane T; Hatanaka K; Yonetani N; Ishii K; Tsudo M; Tanaka H; Yamagami T; Arima N; Anzai N; Aoyama Y; Otsuka Y; Okada M; Murayama T; Hayakawa A; Okamura A; Matsushita A; Kosaka Y; Nagai K; Nakamura F; Higuchi B; Amano I; Sawada H; Yagi H; Sonoki T; Nougawa M; Nakahashi T; Ago H; Ueyama J; Okazaki T; Sayama K; Maeda Y; Ueda Y; Imajo K; Sunami K; Wada H; Hamamoto K; Iwato K; Kobayashi M; Hyodo H; Niimi H; Yujiri T; Abe M; Goto T; Ohnishi H; Imai T; Hara M; Muta T; Narumi H; Kaneko M; Togitani K; Matsuzaki A; Nagafuji K; Abe Y; Nagatoshi Y; Uike N; Imamura Y; Eto T; Morimoto H; Miyaji R; Imada K; Okamura S; Yakushiji K; Kamimura T; Takamatsu Y; Ohno Y; Sueoka E; Miyazaki Y; Moriuchi Y; Hidaka M; Morinaga S; Hashiyama M; Ogata M; Otsuka E; Takatsuka Y; Okamoto Y; Matsushita K; Okamura T; Tomoyose T
  •  go-up   go-down


82. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S: FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood; 2006 Oct 15;108(8):2764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
  • Acute myeloid leukemia (AML) is a clonal disease characterized by heterogeneous involvement of hematopoietic stem cell/progenitor cell populations.
  • Using FLT3 internal tandem duplication (FLT3/ITD) as a molecular marker, we tested the hypothesis that clinical outcome in AML correlates with disease involvement of CD34(+)/CD33(-) precursors.
  • Diagnostic specimens from 24 children with FLT3/ITD-positive AML were sorted by fluorescence-activated cell sorting (FACS), and resultant CD34(+)/CD33(-) and CD34(+)/CD33(+) progenitors were analyzed directly and after colony-forming cell (CFC) assay for the presence of FLT3/ITD.
  • This study suggests that FLT3/ITD involvement in CD34(+)/CD33(-) precursors is heterogeneous and that detection of the mutation in the less-mature progenitor population may be associated with disease resistance.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1721-31 [2469766.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1811-6 [1373089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1345-9 [15959528.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3292-8 [12115363.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):431-5 [14617001.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):150-6 [14701777.001]
  • [Cites] Arch Med Res. 2003 Nov-Dec;34(6):507-14 [14734090.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):413-23 [8439493.001]
  • [Cites] PCR Methods Appl. 1994 Jun;3(6):317-9 [7522723.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2154-61 [7536493.001]
  • [Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]
  • [Cites] N Engl J Med. 1987 Aug 20;317(8):468-73 [3614291.001]
  • (PMID = 16809615.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 114563; United States / NCI NIH HHS / CA / 5T32 CA 009351-27; United States / NCI NIH HHS / CA / U10 CA 98543; United States / NCI NIH HHS / CA / R21 CA 102624; United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / R01 CA 092316; United States / NCI NIH HHS / CA / U24 CA 114766
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC1895585
  •  go-up   go-down


83. Ghosh S, Bandyopadhyay S, Pal S, Das B, Bhattacharya DK, Mandal C: Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia. Br J Haematol; 2005 Jan;128(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia.
  • Disease-specific over-expression of 9-O-acetylated sialoglycoconjugates (9-O-AcSGs) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia (ALL, PBMC(ALL)) has been demonstrated using a lectin, Achatinin-H, with specificity towards 9-O-AcSAalpha2-6GalNAc.
  • [MeSH-major] Glycoconjugates / metabolism. Interferon-gamma / immunology. Leukocytes, Mononuclear / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Sialic Acids / metabolism
  • [MeSH-minor] Adolescent. Cell Proliferation. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Humans. Infant. Lectins / metabolism. Male. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / physiology. Stimulation, Chemical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606547.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoconjugates; 0 / Lectins; 0 / RNA, Messenger; 0 / Sialic Acids; 0 / achatinin(H); 55717-54-9 / 9-O-acetyl-N-acetylneuraminic acid; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


84. Yadav SP, Kalra M, Anjan M, Sachdeva A: Survival outcome in childhood acute lymphoblastic leukemia in India. Pediatr Blood Cancer; 2010 Jan;54(1):178; author reply 179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome in childhood acute lymphoblastic leukemia in India.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


85. Rabin KR, Man TK, Yu A, Folsom MR, Zhao YJ, Rao PH, Plon SE, Naeem RC: Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Aug;51(2):171-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Accurate detection of recurrent chromosomal abnormalities is critical to assign patients to risk-based therapeutic regimens for pediatric acute lymphoblastic leukemia (ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1995 May;13(1):54-61 [7541644.001]
  • [Cites] Leukemia. 2004 May;18(5):939-47 [14999294.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):20-4 [9595040.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] J Med Genet. 2005 Feb;42(2):121-8 [15689449.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):482-94 [16425296.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):492-9 [16999846.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):528-33 [17065418.001]
  • [Cites] PLoS One. 2007;2(3):e327 [17389918.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):805-12 [17539022.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1613-9 [7564498.001]
  • [CommentIn] Pediatr Blood Cancer. 2008 Aug;51(2):153-4 [18300321.001]
  • (PMID = 18253961.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA090433; United States / NCI NIH HHS / CA / CA90433-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS570929; NLM/ PMC4063297
  •  go-up   go-down


86. Forestier E, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology NOPHO: The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol; 2006 Aug;28(8):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations.
  • The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.
  • Almost 80% of the non-Down B-cell precursor ALL cases in the 2 to 7 years frequency peak group who had aberrant cytogenetic results had either a high-hyperdiploid clone (51 to 61 chromosomes) or a translocation t(12;21)(p13;q22).
  • Among B-cell precursor ALL cases, high white blood cell counts correlated with earlier age at diagnosis (rS=-0.23; P<0.001) being most evident for 11q23/MLL-aberrations, translocation t(12;21)(p13;q22), and high-hyperdiploidy.
  • Among acute myeloblastic leukemia patients, frequency peaks were found for those with MLL/11q23 rearrangements (peak: first year), Down syndrome (peak: second to third year), or cytogenetic abnormalities other than translocations t(8;21), t(15;17), and inv(16)/t(16;16) (peak: first to third year).
  • The epidemiology of the cytogenetic subsets of acute leukemias questions whether age as a disease-related prognostic parameter has any relevance in childhood leukemia clinical research beyond being a surrogate marker for more important, truly biologic features such as cytogenetic aberrations and white cell count at diagnosis.
  • Further research is needed to explore whether the 2 to 7 years age incidence peak in childhood ALL harbor yet unidentified cytogenetic subsets with the same natural history as the high-hyperdiploid and t(12;21)-positive leukemias.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912588.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Anirudhan D, Bakhshi S, Xess I, Broor S, Arya LS: Etiology and outcome of oral mucosal lesions in children on chemotherapy for acute lymphoblastic leukemia. Indian Pediatr; 2008 Jan;45(1):47-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and outcome of oral mucosal lesions in children on chemotherapy for acute lymphoblastic leukemia.
  • Microbiological cultures were taken from oral cavity and blood in 100 mucositis episodes in 70 children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Mouth Mucosa / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Stomatitis / microbiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250506.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


88. Forman SJ: Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor? Nat Clin Pract Oncol; 2005 Jan;2(1):18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Transplantation, Autologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264849.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


89. Ryningen A, Stapnes C, Bruserud Ø: Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk Res; 2007 Sep;31(9):1303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
  • Differentiation-inducing therapy with the DNA-methylation inhibitor Decitabine (5'-aza-deoxycytidine) and histone deacetylase (HDAC) inhibitors are now considered in acute myelogenous leukemia (AML).
  • The colonies showed differences in morphology, viability, cell cycle distribution and expression of differentiation markers.
  • Both Decitabine and the two HDAC inhibitors altered AML cell expression of differentiation markers, whereas the drugs did not have any major influence on cell cycle distribution.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation. Epigenesis, Genetic / drug effects. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Cycle / drug effects. Cell Proliferation. DNA, Mitochondrial / metabolism. Enzyme Inhibitors / pharmacology. Female. Histone Deacetylase Inhibitors. Humans. Hydroxamic Acids / pharmacology. Male. Middle Aged. Myelodysplastic Syndromes / drug therapy. Phenylbutyrates / pharmacology. Thymidine / metabolism. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416413.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Mitochondrial; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Phenylbutyrates; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; 7WY7YBI87E / 4-phenylbutyric acid; M801H13NRU / Azacitidine; VC2W18DGKR / Thymidine
  •  go-up   go-down


90. Wolach B, Ash S, Gavrieli R, Stark B, Yaniv I, Roos D: Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report. Am J Hematol; 2005 Sep;80(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report.
  • We report for the first time a child with chronic granulomatous disease (CGD) who developed acute lymphoblastic leukemia (ALL).
  • He was found to have a deficiency of the gp91(phox) subunit of the leukocyte NADPH oxidase, with the X-linked inheritance of the disease.
  • DNA analysis revealed a C nucleotide insertion between C1028 and T1029.
  • At the age of 16 months, the patient developed T-cell ALL.
  • He was treated for 2 years, and today, 10 years since the diagnosis, he is disease-free.
  • [MeSH-major] Granulomatous Disease, Chronic / genetics. Membrane Glycoproteins / genetics. Mutation. NADPH Oxidase / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Chronic Granulomatous Disease.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138344.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CYBB protein, human; 0 / Membrane Glycoproteins; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


91. Vanura K, Vrsalovic MM, Le T, Marculescu R, Kusec R, Jäger U, Nadel B: V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2009 Aug;48(8):725-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia.
  • Translocations of proto-oncogenes to the B-cell or T-cell antigen receptor loci in acute T- or B-cell leukemia and lymphoma have been, in most cases, accredited to V(D)J or switch recombination depending on the location of the breakpoint at the receptor locus.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes / genetics. Recombination, Genetic. Translocation, Genetic. VDJ Recombinases / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cells, Cultured. DNA Breaks. DNA-Binding Proteins / genetics. Fibroblasts. Genes, T-Cell Receptor. Homeodomain Proteins / genetics. LIM Domain Proteins. Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / genetics. Metalloproteins / genetics. Mice. Receptors, Antigen, B-Cell / genetics. TCF Transcription Factors / genetics. Transcription Factor 7-Like 1 Protein

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455608.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / Lmo2 protein, mouse; 0 / Metalloproteins; 0 / Receptors, Antigen, B-Cell; 0 / TCF Transcription Factors; 0 / Tcf7l1 protein, mouse; 0 / Tlx1 protein, mouse; 0 / Transcription Factor 7-Like 1 Protein; EC 2.7.10.2 / Lymphocyte Specific Protein Tyrosine Kinase p56(lck); EC 2.7.7.- / VDJ Recombinases
  •  go-up   go-down


92. Ohnishi K: PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol; 2007 Oct;12(5):313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
  • Acute promyelocytic leukemia (APL) is characterized by generation of the PML-RARalpha fusion gene.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / antagonists & inhibitors. Oxides / therapeutic use. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71 [11587370.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]
  • [Cites] Cell. 1997 May 2;89(3):373-80 [9150137.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]
  • [Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Ann Intern Med. 2000 Dec 5;133(11):881-5 [11103058.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21486-91 [1328234.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Blood. 2007 Jul 1;110(1):59-66 [17374742.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] J Med Chem. 1988 Nov;31(11):2182-92 [3184125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(11):696-8 [7593136.001]
  • [Cites] Leukemia. 2002 Apr;16(4):617-22 [11960341.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):454-7 [7566127.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Nature. 1989 Jun 29;339(6227):714-7 [2544807.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1573-7 [8395911.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93 [16937107.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Arch Biochem Biophys. 1980 Feb;199(2):374-83 [7362233.001]
  • [Cites] Ann Intern Med. 1996 May 15;124(10):893-6 [8610919.001]
  • [Cites] Blood. 1996 Jan 15;87(2):725-33 [8555497.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:147-55 [17124054.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • (PMID = 17929112.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Benzoates; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Tetrahydronaphthalenes; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 08V52GZ3H9 / tamibarotene; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 46
  •  go-up   go-down


93. Radomska HS, Bassères DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG, Tenen DG: Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med; 2006 Feb 20;203(2):371-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
  • Mutations constitutively activating FLT3 kinase are detected in approximately 30% of acute myelogenous leukemia (AML) patients and affect downstream pathways such as extracellular signal-regulated kinase (ERK)1/2.
  • In contrast, there was no effect when serine 21 was mutated to aspartate (S21D), which mimics phosphorylation of C/EBPalpha.
  • Thus, our results suggest that therapies targeting the MEK/ERK cascade or development of protein therapies based on transduction of constitutively active C/EBPalpha may prove effective in treatment of FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies.


94. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A: Rapamycin for refractory acute graft-versus-host disease. Transplantation; 2009 Nov 15;88(9):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin for refractory acute graft-versus-host disease.
  • Steroid-refractory acute graft-versus-host disease (GVHD) remains a significant cause of mortality after allogeneic stem-cell transplantation and therapeutic options are not codified.
  • METHODS: In this retrospective single-center study, 22 patients were identified, from October 2004 to February 2008, as having received rapamycin for acute GVHD refractory to one or more lines of treatment.
  • CONCLUSION: Despite a small and heterogeneous population of patients, these results are encouraging and provide a rationale for prospective studies that use rapamycin in steroid-refractory acute GVHD as a second- or third-line agent.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / therapeutic use. Leukemia / surgery. Sirolimus / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bacterial Infections / epidemiology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Middle Aged. Retrospective Studies. Survival Rate. Survivors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898203.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


95. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol; 2009 Feb 10;27(5):791-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
  • PURPOSE: Therapy-related myelodysplasia or acute myelogenous leukemia (t-MDS/AML) is a lethal complication of autologous hematopoietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • These telomere alterations preceded the onset of t-MDS and were independent of other known risk factors associated with development of t-MDS/AML on multivariate analysis.


96. Steinberg JD, Olver CS, Davis WC, Arzt J, Johnson J, Callan R: Acute myeloid leukemia with multilineage dysplasia in an alpaca. Vet Clin Pathol; 2008 Sep;37(3):289-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with multilineage dysplasia in an alpaca.
  • Based on their morphology, the cells were interpreted to be progranulocytes and myeloblasts, and a presumptive diagnosis of acute myeloid leukemia (AML) was made.
  • The blast cells accounted for 60% of the nucleated cell population on bone marrow aspirates, further supporting a diagnosis of AML with multilineage dysplasia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761521.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C: Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant; 2007 Dec;13(12):1461-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
  • Few studies have tested the benefits of using peripheral blood stem cell (PBSC) grafts versus bone marrow (BM) grafts for unrelated donor transplantation.
  • We compared outcomes after 331 PBSC and 586 BM transplants in adults with leukemia and myelodysplastic syndrome (MDS) who were followed for a median of 3 years after transplantation.
  • PBSC recipients were less likely to have chronic myelogenous leukemia (CML) and more likely to have MDS, to have poor performance scores, and to be transplanted more recently.
  • Rates of grades 2-4 acute graft-versus-host disease (GVHD) (58% versus 45%, P < .001) and chronic GVHD (cGVHD) (56% versus 42%, P < .001) were significantly higher with PBSC than with BM transplants.
  • The 3-year probabilities of treatment-related mortality (TRM), leukemia recurrence, leukemia-free, and overall survival (OS) were similar in the 2 groups with 3-year leukemia-free survival rates of 30% and 32% after transplantation of PBSC and BM, respectively.
  • Unlike results after HLA-matched sibling donor PBSC transplants, we did not identify a survival advantage with PBSC grafts in patients receiving unrelated donor transplants for advanced leukemia.

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] Hum Immunol. 2007 Jan;68(1):30-40 [17207710.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):27-33 [11244435.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1739-45 [11535506.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 Jul 15;100(2):415-9 [12091330.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3128-34 [12384409.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(1):23-9 [12621503.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2459-64 [2350582.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Blood. 2005 Jan 15;105(2):548-51 [15367429.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4288-90 [16946302.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • (PMID = 18022576.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076518-08; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / U24-CA76518-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS35024; NLM/ PMC2267869
  •  go-up   go-down


98. Rowe JM: Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. Best Pract Res Clin Haematol; 2008 Sep;21(3):485-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
  • The graft-versus-leukaemia effect is one of the most important biological effects to influence outcome in patients with acute leukaemia.
  • The recognition of this modality over the past three decades has led to far-reaching changes in the concept and conduct of allogeneic transplantation in acute myeloid leukaemia, and in the infusion of donor lymphocytes as a therapeutic modality.
  • Despite these conceptual advances, there is a considerable need for more structured prospective studies to optimally define the role of reduced-intensity transplantation in both acute myeloid and acute lymphoblastic leukaemia.
  • [MeSH-major] Graft vs Host Disease / immunology. Leukemia / immunology. Leukemia, Myeloid, Acute / immunology. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / immunology
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cells / immunology. Humans


99. Paulsson K, Heidenblad M, Mörse H, Borg A, Fioretos T, Johansson B: Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia; 2006 Nov;20(11):2002-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploidy, characterized by non-random trisomies, is the largest cytogenetic subgroup in childhood acute lymphoblastic leukemia (ALL).
  • In conclusion, the array CGH analyses revealed putative leukemia-associated submicroscopic imbalances and rearrangements in 2/8 (25%) hyperdiploid ALLs.
  • [MeSH-major] Genomics / methods. In Situ Hybridization, Fluorescence / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


100. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG, Venzon D, Raina V: Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer; 2005 Jul;41(11):1570-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
  • In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia (ALL) in children and young adults (less than 25 years) in India were poor, even in specialised cancer centres.
  • The introduction of a standard treatment protocol (MCP841) and improvements in supportive care in three major cancer centres in India led to an increase in the event-free survival rate (EFS) from less than 20% to 45-60% at 4 years.
  • Total white blood cell count (WBC) was the only statistically significant risk factor identified in multivariate analyses in two of the centres.
  • Comparison of patient characteristics with published series from Western nations indicated that patients from all three Indian centres had more extensive disease at presentation, as measured by WBC, lymphadenopathy and organomegaly.
  • The proportions of ALLs with precursor T-cell immunophenotypes, particularly in Chennai, were also increased, even when differences in the age distribution were taken into consideration (in <18-year olds, the range was 21.1-42.7%), and in molecular analyses performed on leukaemic cells from over 250 patients less than 21-years-old with precursor B-cell ALL, a lower frequency of TEL-AML1-positive ALL cases than reported in Western series was observed.
  • The worse outcome of treatment in Indian patients compared with recent Western series was probably due to the higher rate of toxic deaths in the Indian patients, and possibly also due to their more extensive disease - which is, at least partly, a consequence of delay in diagnosis.
  • The higher toxic death rates observed are likely to have arisen from a combination of more extensive disease at diagnosis, co-morbidities (e.g., intercurrent infections), differences in the level of hygiene achievable in the average home, poor access to acute care, and more limited supportive care facilities in Indian hospitals.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. India. Infant. Male. Multicenter Studies as Topic. Multivariate Analysis. Recurrence. Risk Factors. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Cancer. 2007 Feb;43(3):632. Raina, V [added]
  • (PMID = 16026693.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down






Advertisement